Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/5/2018
SIETES contiene 92334 citas

 
 
 1 a 20 de 22434 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry 2018:7 de mayo. [Ref.ID 102604]
2. Cita con resumen
Swetlitz I. Gottlieb pushes back against criticism of ‘breakthrough’ designation. STAT Daily Recap 2018:5. [Ref.ID 102595]
3.Enlace a cita original Cita con resumen
Webster P. Pimavanserin evaluated by the FDA. Lancet 2018;391:5 de mayo. [Ref.ID 102594]
4.Enlace a cita original Cita con resumen
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Mozley LH, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102593]
5.Enlace a cita original Cita con resumen
Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, Selby P. Cardiovascular and neuropsychiatric events after varenicline use for smoking cessation. Am J Respir Crit Care Med 2018;197:913-22. [Ref.ID 102579]
6. Cita con resumen
Elia J. Celecoxib gets partial exoneration from FDA panels. Physician's First Watch 2018:5. [Ref.ID 102574]
7. Cita con resumen
Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug-related morbidity and mortality.. Annals of Pharmacotherapy 2018:26 de marzo. [Ref.ID 102573]
9.Enlace a cita original Cita con resumen
Bergman JEH, Lutke LR, Gans ROB, Addor M-C, Barisic I, Clavero-Carbonell C, Garne E, Gatt M, Klungsoyr K, Lelong N, Lynch C, Mokoroa O, Nelen V, Neville AJ, Pierini A, Randrianaivo H, Rißmann A, Tucker D, Wiesel A, Dolk H, Loane M, Bakker MK. Beta-blocker use in pregnancy and risk of specific congenital anomalies: A European case-malformed control study. Drug Saf 2018;41:415-27. [Ref.ID 102566]
10.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
11.Enlace a cita original Cita con resumen
Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med 2018;168:20 de marzo. [Ref.ID 102564]
12.Enlace a cita original Cita con resumen
Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel Jr EF, Grijalva CG. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case-control study. Ann Intern Med 2018;168:20 de marzo. [Ref.ID 102563]
13.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:21 de marzo. [Ref.ID 102562]
14.Enlace a cita original Cita con resumen
Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, Hansen AV, de Jong-van den Berg LTW, Jordan S, Klungsøyr K, Neville AJ, Pierini A, Puccini A, Sinclair M, Dolk DTH. The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. Eur J Clin Pharmacol 2018;74:abril. [Ref.ID 102561]
15.Enlace a cita original Cita con resumen
Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neurospychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf 2018;41:marzo. [Ref.ID 102559]
16.Enlace a cita original Cita con resumen
Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol 2018;154:1 de abril. [Ref.ID 102558]
17. Cita con resumen
Anónimo. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. European Medical Agency 2018:1. [Ref.ID 102552]
18. Cita con resumen
Anónimo. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta. European Medical Agency 2018:7 de marzo. [Ref.ID 102551]
19.Enlace a cita original Cita con resumen
Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]
20.Enlace a cita original Cita con resumen
Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. [Ref.ID 102549]
Seleccionar todas
 
 1 a 20 de 22434 siguiente >>